Skip to content
Parsabiv(velcalcetide)
Parsabiv (velcalcetide) is a protein pharmaceutical. Velcalcetide was first approved as Parsabiv on 2016-11-11. It has been approved in Europe to treat secondary hyperparathyroidism. It is known to target extracellular calcium-sensing receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
endocrine system diseasesD004700
Trade Name
FDA
EMA
Parsabiv
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etelcalcetide
Tradename
Company
Number
Date
Products
PARSABIVKAI PharmaceuticalsN-208325 RX2017-02-07
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
parsabivNew Drug Application2021-02-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Etelcalcetide, Parsabiv, Kai Pharms Inc
98209382034-06-27DP
103447652034-06-27DP
111625002034-06-27DP
89999322031-02-07DS, DPU-2014
83778802030-07-29DS, DP
92789952030-07-29DP
97017122030-07-29DS, DPU-2014
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05B: Anti-parathyroid agents
— H05BX: Other anti-parathyroid agents in atc
— H05BX04: Etelcalcetide
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Secondary hyperparathyroidismD006962EFO_1001173549——18
Chronic renal insufficiencyD051436N18——3——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vascular calcificationD061205—1———1
Chronic kidney disease-mineral and bone disorderD012080EFO_1001152N25.0—1———1
Chronic kidney failureD007676EFO_0003884N18.6—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVELCALCETIDE
INNetelcalcetide
Description
Etelcalcetide is an oligopeptide.
Classification
Protein
Drug classpeptides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O
Identifiers
PDB—
CAS-ID1262780-97-1
RxCUI1876119
ChEMBL IDCHEMBL3545184
ChEBI ID—
PubChem CID71511839
DrugBankDB12865
UNII ID60ME133FJB (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CASR
CASR
Organism
Homo sapiens
Gene name
CASR
Gene synonyms
GPRC2A, PCAR1
NCBI Gene ID
846
Protein name
extracellular calcium-sensing receptor
Protein synonyms
parathyroid Ca(2+)-sensing receptor 1, Parathyroid cell calcium-sensing receptor 1, PCaR1
Uniprot ID
Q4PJ19
Mouse ortholog
Casr (12374)
extracellular calcium-sensing receptor (Q9R1Y2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 284 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
548,173 adverse events reported
View more details